GC
NBSE

Gratia Capital’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Gratia Capital’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-121
Closed -$658K – 58
2014
Q1 		$658K Buy
+121
New +$637K 0.29% 44

Other funds holding NBSE

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Gratia Capital's NBSE Position: Q2 2014 in Review

Gratia Capital sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2014, closing a stake of 121 shares — an estimated $658K sold.

Gratia Capital first reported a position in NBSE in Q1 2014 and held it in 1 quarter. The position peaked at $658K in Q1 2014. 57 funds tracked by Wall St. Rank hold NBSE as of Q2 2014.

  • Gratia Capital reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • Gratia Capital sold 121 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2014, an estimated $658K.
  • Gratia Capital first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2014 and held it in 1 quarter.
  • Gratia Capital's NeuBase Therapeutics, Inc. Common Stock position peaked at $658K in Q1 2014.
  • 57 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2014.

Based on Gratia Capital's 13F filing for Q2 2014, filed 7 Aug 2014.